Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16534336 | 1.00 | IDO1 (0.46) | IDO1POLBMAPK1SLC6A2SLC6A4 | |
| SCHEMBL13849900 | 0.88 | PPARG (0.45) | IDO1POLBMAPK1SLC6A2SLC6A4 | |
| SCHEMBL14402485 | 0.88 | PPARG (0.45) | IDO1POLBMAPK1SLC6A2SLC6A4 | |
| SCHEMBL13003553 | 0.85 | IDO1 (0.46) | IDO1POLBMAPK1SLC6A2SLC6A4 | |
| SCHEMBL16534653 | 0.83 | IDO1 (0.47) | IDO1SLC6A2SLC6A4PPARGEPHX2 | |
| SCHEMBL2426168 | 0.83 | IDO1 (0.47) | IDO1SLC6A2SLC6A4PPARGEPHX2 | |
| SCHEMBL28982570 | 0.80 | IDO1 (0.44) | IDO1SLC6A2SLC6A4PPARGEPHX2 | |
| SCHEMBL6203603 | 0.79 | IDO1 (0.47) | IDO1SLC6A2SLC6A4PPARGEPHX2 | |
| SCHEMBL320896 | 0.79 | IDO1 (0.50) | IDO1POLBSLC6A2SLC6A4PPARG | |
| SCHEMBL7508666 | 0.77 | EPHX2 (0.53) | IDO1POLBMAPK1PPARGEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834233-B1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORP (FI) | 2018-04-25 | — | — | EP | disclosed |
| US-9249127-B2 | Alpha2 adrenoceptor agonists | ORION CORPORATION (FI) | 2016-02-02 | — | — | US | disclosed |
| US-20150065550-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORPORATION (FI) | 2015-03-05 | — | — | US | disclosed |
| EP-2834233-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | Orion Corporation (FI) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013150173-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ORION CORPORATION (FI) | 2013-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065550-A1 | NEW ALPHA2 ADRENOCEPTOR AGONISTS | ADRA2A, ADRB2, ADRA2C | IDO1 2450/4885POLB 3044/4885MAPK1 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.